Atlas Trials

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Clinical trial NCT01463891 · COMPLETED

Trial details

NCT number
NCT01463891
Sponsor
Eisai Co., Ltd.
Status
COMPLETED
Study type
OBSERVATIONAL
Inoperable or Recurrent Breast Cancer
Start date
2011-07-19
Primary completion
2012-12-26
Enrollment
963

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.